Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma

2002 ◽  
Vol 47 (6) ◽  
pp. 956-961 ◽  
Author(s):  
Michael Shapiro ◽  
Alain H. Rook ◽  
Michael S. Lehrer ◽  
Jacqueline M. Junkins-Hopkins ◽  
Lars E. French ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Ultraviolet A ◽  
Response Modifier ◽  
Long Wave ◽  
Biologic Response ◽  
Biologic Response Modifier

Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.

1991 ◽  
Vol 9 (4) ◽  
pp. 565-571 ◽  
Author(s):  
F J Cummings ◽  
K Kim ◽  
R S Neiman ◽  
R L Comis ◽  
M M Oken ◽  
...  
Keyword(s):  
T Cell ◽  
Hodgkin's Disease ◽  
Cell Lymphoma ◽  
Hodgkin’S Disease ◽  
Eastern Cooperative Oncology Group ◽  
Response Duration ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Biologic Response ◽  
Poorly Differentiated

Thirty-seven patients with refractory lymphoma or cutaneous T-cell lymphoma were treated with 2'-deoxycoformycin (pentostatin; dCF), 5 mg/m2 intravenous (IV) bolus for 3 consecutive days of every 3-week cycle in this Eastern Cooperative Oncology Group (ECOG) trial. Included were 25 with the diagnosis of non-Hodgkin's lymphoma, three with Hodgkin's disease, eight with cutaneous T-cell lymphoma (CTCL), and one with unknown subtype, of whom 31 were considered eligible. The majority had failed at least two, but no more, conventional chemotherapy regimens. Ten (32%) of the eligible patients had a partial response (PR), including patients with nodular poorly differentiated lymphocytic (NPDL), nodular mixed (NM), diffuse poorly differentiated lymphocytic (DPDL), or diffuse histiocytic (DH), lymphoma mixed-cellularity (MC), Hodgkin's disease, and unknown subtype, and in four patients with CTCL. The overall median time to treatment failure (TTF) was only 1.3 months, but the range extended to 57.3 months. The overall response duration was 16.0 months, and the range extended to 53.4 months. Overall median survival was 2.7 months, with the range extending to 63.2 months. The majority of patients had no toxicity, but there were some instances of severe or life-threatening events. Four fatal toxicities occurred, in two patients with underlying pulmonary conditions and two with prior cardiac histories. From this study, we conclude that dCF is active in refractory lymphomas and CTCLs, should be avoided in patients with a history of serious pulmonary or cardiac diseases, and warrants consideration for incorporation of a low-dosage schedule into conventional combination chemotherapy regimens, including its use with biologic response modifiers.

scholarly journals Long-Term Efficacy of Psoralen Plus Ultraviolet a Irradiation and Low-Dose Interferon-Alpha Therapy According to Conventional and Emerging Clinical Endopoints of Early Stage Cutaneous T Cell Lymphoma

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 2462-2462
Author(s):  
Serena Rupoli ◽  
Gaia Goteri ◽  
Erika Morsia ◽  
Elena Torre ◽  
Kimberly Blaine Garvey ◽  
...  
Keyword(s):  
T Cell ◽  
Median Time ◽  
Partial Remission ◽  
Low Dose ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Ultraviolet A

Abstract Introduction: Patients with early stage Cutaneous T cell Lymphoma (CTCL) usually have a benign and chronic disease course. Refractoriness under skin directed therapies and/or more extensive disease pose some therapeutic changes. Using the combination of psoralen plus ultraviolet A irradiation (PUVA) and low-dose Interferon-α (INF), the principal treatment goal is to keep confined the disease to the skin, preventing disease progression. Methods: We carry out a prospective data on 87 patients with early stage IA to IIA MF treated with low-dose IFN-α2b and PUVA, enrolled from 1997 to 2010. We collected data regarding clinical characteristics of MF, efficacy and outcome. Subcutaneous IFN-α2b was administered 1.5 MU/day during the first week; in the second week the dose was increased to 3MU/day. PUVA irradiation was started on the 3th week with IFN-α2b 3 MU 3 times weekly until CR, of for a maximum of 2 months. During maintenance therapy, IFN-α2b was scheduled for 3 MU 3 times weekly for 2 months and subsequently 3 MU 2 times weekly for 10 months and PUVA was gradually reduced every 2 months over a period of 12 months. Diagnostic, risk and response assignments were according to EORTC criteria. Results: Patient characteristics at time diagnosis, staging, response rates and overall outcome are shown in Table 1. Among the 87 patients, overall response rate (ORR) was 97.8% (n=85) and included complete remission (CR) in 70 patients (80.5%), very good partial remission in 5 patients (5.8%) and partial remission (PR) in another 10 (11.5%). The best response to therapy was seen after a median of 5 months (range, 1-30) and the 74.3% of patients who achieved a CR after induction therapy kept the complete response at the last follow up. Among the responders, 40 (47.1%) relapsed with minor event with in median time of 21 months (range, 0-71) and 7(8.2%) relapsed with major event in a median time of 6 months (range, 1-81). After a median follow up of 207 months (range, 6-295), 25 (28.7) patients died, only 1 for progressive disease. Median overall survival (OS) for our cohort was not reached (95% CI; 235-NR months) and median time to next treatment (TTNT) was 38.5 months (95% CI, 33-46 months). Moreover, disease free survival (DFS) in CR patients was 210 months (95% CI; 200-226 months). Conclusions: The long follow up of this study verifies our preliminary results and confirms the efficacy of INF-PUVA combination therapy in a real world setting, according conventional (OS and DFS) and emerging (TTNT) clinical endpoints of treatment efficacy. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma

2011 ◽  
Vol 65 (1) ◽  
pp. 212-214 ◽  
Author(s):  
Brian A. Raphael ◽  
Kelly A. Morrissey ◽  
Ellen J. Kim ◽  
Carmela C. Vittorio ◽  
Alain H. Rook
Keyword(s):  
T Cell ◽  
Peripheral Blood ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Ultraviolet A ◽  
Blood Disease
Sign in / Sign up

Export Citation Format

Share Document